Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Lemtrada Safety Issues Lead To Use Restrictions In Europe

November 26, 2019 By Law Offices of Thomas J. Lamb, P.A.

Drug safety regulators for the European Union recently recommended that Lemtrada use be restricted to certain limited patient populations due to serious side effects linked to Lemtrada. This November 5, 2019 Multiple Sclerosis News Today report, “EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals … [Read more...]

Filed Under: Unsafe Drugs Tagged With: bleeding disorders, bleeding in the lungs, Heart Attacks, Hepatitis, Lemtrada, liver damage, Strokes

Lemtrada Drug Safety Update: Use Restrictions And Patient Monitoring For Side Effects

July 9, 2019 By Law Offices of Thomas J. Lamb, P.A.

On May 17, 2019 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued this Lemtrada Drug Safety Update, “Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements”, we get this summary: While an urgent [European Union (EU)] safety … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Autoimmune Hepatitis, Heart Attacks, Lemtrada, Strokes

Uloric Lawsuits Follow Recent FDA Warnings About Heart-Related Deaths And Side Effects

May 1, 2019 By Law Offices of Thomas J. Lamb, P.A.

Following recent FDA-mandated label changes, there have been Uloric lawsuits filed against Takeda Pharmaceuticals America, Inc., the manufacturer of Uloric. Uloric (febuxostat) tablets have been generally prescribed for the management of chronic gout since 2009. In February 2019 the FDA required its strongest safety warning, i.e., Bolded … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, Heart Attacks, Strokes, Uloric

Zelnorm: FDA Approval In 2019 (After 2007 Recall) Despite Continuing Cardiovascular Safety Concerns

April 29, 2019 By Law Offices of Thomas J. Lamb, P.A.

In April 2019 we learned that the FDA is allowing Zelnorm back on the market 12 years after there was an FDA-mandated Zelnorm recall. From this April 3, 2019 Healio article, “FDA approves reintroduction of Zelnorm for IBS-C in certain women”, we get this significant point: Sloan Pharmaceuticals [(the responsible drug company)], a subsidiary of … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cardiovascular events, Heart Attacks, Myocardial Infarctions (MI), Strokes, Zelnorm

February 2019: Uloric “Black-Box Warning” For Heart-Related Deaths, Cardiovascular Side Effects

March 5, 2019 By Law Offices of Thomas J. Lamb, P.A.

The FDA has required its strongest safety warning, i.e., Bolded Warning or Black-Box Warning, be included on a new Uloric drug label to inform about the increased risk of heart-related death and death from all causes with Uloric. From this February 2019 FDA Drug Safety Communication, "FDA adds Boxed Warning for increased risk of death with gout … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cardiovascular events, Heart Attacks, heart-related deaths, Myocardial Infarctions (MI), nonfatal myocardial infarctions, Strokes, Uloric

November 2017 FDA Alert: Uloric May Increase Heart-Related Deaths Risk

November 17, 2017 By Law Offices of Thomas J. Lamb, P.A.

On November 15, 2017 there was an email sent by the FDA about this MedWatch Safety Alert, “Febuxostat (Brand Name Uloric): Drug Safety Communication – FDA to Evaluate Increased Risk of Heart-related Death”, from which we get this excerpt: ISSUE: FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cerebral Vascular Accident (CVA), Cerebrovascular Accidents, Heart Attacks, heart-related deaths, Strokes, Uloric

J&J Tries to Expand Invokana Label to Include Cardiovascular Benefits

October 9, 2017 By Law Offices of Thomas J. Lamb, P.A.

Johnson & Johnson's, the drug manufacturer of diabetes drugs Invokana, Invokamet, and Invokamet XR, recently submitted a supplemental new drug application (sNDA) to the FDA to request expansion of the labels for these drugs. If granted, the new label would include a cardiovascular indication concerning the reduction of risk of cardiovascular … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, diabetes drugs amputation, diabetes drugs side effects, drug label changes, FDA, foot amputations, Heart Attacks, Invokamet, invokamet xr, Invokana, johnson & johnson's, leg amputations, nonfatal myocardial infarctions, sNDA, supplemental new drug application, toe amputations, type 2 diabetes drugs

Pradaxa And Xarelto May Double The Risk Of Heart Attacks Some Patients

April 18, 2017 By Law Offices of Thomas J. Lamb, P.A.

In March 2017 the British Journal of Clinical Pharmacology published this article, “Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants”, which reports on the first retrospective cohort study to compare the risk of acute myocardial infarction (AMI), or heart … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Heart Attacks, Myocardial Infarctions (MI), Pradaxa, Xarelto

Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning

August 31, 2016 By Law Offices of Thomas J. Lamb, P.A.

In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), and Xigduo XR (dapagliflozin and metformin extended-release). As for the other diabetes … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Acute Kidney Injury, Cerebral Vascular Accident (CVA), Deep Vein Thrombosis (DVT), Farxiga, Glyxambi, Heart Attacks, Invokamet, Invokana, Ischemic Stroke, Jardiance, Ketoacidosis, Kidney Damage, Kidney Failure, Myocardial Infarctions (MI), Pulmonary Embolism (PE), Pyelonephritis, Renal Failure, Synjardy, Urinary Tract Infection (UTI), Urosepsis, Xigduo

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2021 · Law Offices of Thomas J. Lamb, P.A.